Theravance Biopharma, Inc.
NASDAQ:TBPH
9.86 (USD) • At close December 26, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||||||
| Net Income
| -55.193 | -92.824 | -199.426 | -278.017 | -236.455 | -215.524 | -285.405 | -190.669 | -182.219 | -237.038 | -156.284 | -9.575 | -109.335 |
| Depreciation & Amortization
| 4.256 | 7.024 | 9.708 | 9.063 | 6.214 | 3.166 | 4.027 | 3.119 | 2.989 | 2.662 | 2.653 | 3.251 | 3.844 |
| Deferred Income Tax
| 3.207 | 0 | -44.477 | 15.464 | 0 | -11.208 | 8.74 | 0.282 | 2.171 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 25.371 | 39.734 | 62.061 | 62.976 | 60.45 | 51.313 | 49.145 | 41.169 | 54.05 | 43.234 | 22.476 | 21.323 | 0 |
| Change In Working Capital
| -8.34 | 42.35 | -39.584 | -39.462 | -45.4 | 59.429 | 22.431 | 46.928 | -37.783 | 12.77 | 10.176 | -134.302 | -1.845 |
| Accounts Receivables
| 0 | -2.72 | 1.803 | 6.128 | -11.323 | 1.633 | -1.607 | 1.276 | -1.633 | -0.09 | -0.199 | -2.707 | 1.303 |
| Inventory
| 0 | 0 | -26.39 | -22.525 | 1.442 | -1.629 | -7.301 | -3.182 | 1.03 | -6.628 | -3.101 | -4.822 | 1.709 |
| Accounts Payables
| 0.006 | -1.612 | -3.534 | 3.658 | -4.274 | 3.575 | 3.796 | -16.436 | 8.717 | 3.917 | 2.113 | -1.532 | 3.312 |
| Other Working Capital
| -8.346 | 46.682 | -11.463 | -26.723 | -31.245 | 55.85 | 27.543 | 65.27 | -45.897 | 15.571 | 11.363 | -125.241 | -8.169 |
| Other Non Cash Items
| 3.702 | -183.275 | 3.86 | -20.427 | -23.006 | -0.043 | 0.01 | 0.182 | -8.065 | 3.217 | 0.02 | 0.196 | 23.908 |
| Operating Cash Flow
| -26.997 | -186.991 | -207.858 | -250.403 | -238.197 | -112.867 | -201.052 | -98.989 | -168.857 | -175.155 | -120.959 | -119.107 | -83.428 |
| Investing Activities: | |||||||||||||
| Investments In Property Plant And Equipment
| -2.488 | -0.572 | -3.406 | -6.616 | -3.176 | -7.24 | -2.406 | -2.135 | -2.647 | -3.107 | -2.734 | -2.59 | -3.627 |
| Acquisitions Net
| 0 | 4.575 | 0.006 | 0.064 | 5 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -134.534 | -103.145 | -158.305 | -401.987 | -423.898 | -183.261 | -288.791 | -237.567 | -73.011 | -168.893 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 102.812 | 158.017 | 286.199 | 419.26 | 339.018 | 347.192 | 234.864 | 91.467 | 186.697 | 66.442 | 0 | 0 | 0 |
| Other Investing Activites
| 1.513 | 1,095.134 | 127.9 | 17.337 | 0.005 | 0.017 | -53.927 | -146.1 | 113.686 | -0.693 | 0.1 | 0.16 | 0.575 |
| Investing Cash Flow
| -32.697 | 1,154.009 | 124.494 | 10.721 | -83.051 | 176.708 | -56.333 | -148.235 | 111.039 | -106.251 | -2.634 | -2.43 | -3.052 |
| Financing Activities: | |||||||||||||
| Debt Repayment
| 0 | -631.603 | -10.73 | 144.653 | -2.152 | 229.441 | 0 | 222.498 | 0 | 0 | 0 | -0.069 | -0.206 |
| Common Stock Issued
| 0 | 0 | 108.18 | 139.915 | 3.474 | 0 | 0 | 253.028 | 79.017 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| -199.551 | -132.28 | -9.061 | -9.749 | -3.173 | -9.807 | -8.56 | -3.871 | -0.756 | -0.178 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| 0.618 | 5.077 | 3.471 | -11.734 | 3.443 | 5.566 | 10.216 | 7.571 | 3.049 | 370.799 | 123.593 | 121.606 | 86.686 |
| Financing Cash Flow
| -198.933 | -758.806 | 91.86 | 263.085 | 1.291 | 225.2 | 1.656 | 479.226 | 81.31 | 370.621 | 123.593 | 121.537 | 86.48 |
| Other Information: | |||||||||||||
| Effect Of Forex Changes On Cash
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 281.406 | 0 | 0 | 0 |
| Net Change In Cash
| -258.627 | 208.212 | 8.496 | 23.403 | -319.957 | 289.041 | -255.729 | 232.002 | 23.492 | 370.621 | 0 | 0 | 0 |
| Cash At End Of Period
| 40.381 | 299.008 | 90.796 | 82.3 | 58.897 | 378.854 | 88.98 | 344.709 | 112.707 | 89.215 | 0 | 0 | 0 |